ORBIMED ADVISORS LLC
Q4 2020 13F-HR Holdings
Net value change ($000)
+3,471,857
(43.6%)
New positions
26
Sold out positions
19
Turnover %
16.4%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q3 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| PRLD | 645,939 | 137.5% |
| SPRY | 405,053 | NEW |
| ABCL | 338,047 | NEW |
| PMVP | 190,664 | 73.3% |
| SpringWorks Therapeutics, Inc. | 184,046 | 52.1% |
| Prevail Therapeutics Inc. | 178,171 | 126.6% |
| Kinnate Biopharma Inc. | 153,071 | NEW |
| UNH | 136,870 | NEW |
| PFE | 133,127 | NEW |
| ELV | 99,698 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| ALXN | -223,567 | -89.4% |
| BIIB | -73,458 | -36.2% |
| XLRN | -67,638 | -100.0% |
| EXEL | -58,780 | -100.0% |
| ASND | -57,227 | -50.5% |
| ELDN | -54,435 | -100.0% |
| NVO | -22,912 | -100.0% |
| BNR | -22,897 | -19.2% |
| Tricida, Inc. | -19,324 | -22.2% |
| IVERIC bio, Inc. | -19,243 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
9,754
(0.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|